Sofinnova Partners

Signadori Bio is a biopharmaceutical company dedicated to developing innovative cellular immunotherapy treatments for cancer. It operates in the cell and gene therapy space, aiming to advance novel approaches in oncology to help doctors combat cancer more effectively.

GenSight Biologics S.A. is a clinical-stage biotechnology company based in Paris, France, focused on the discovery and development of gene therapies for retinal degenerative diseases and neurodegenerative disorders of the central nervous system. Founded in 2012, the company utilizes innovative technologies, including mitochondrial targeting sequences and optogenetics, to develop treatments that aim to preserve or restore vision in patients with severe vision impairments. Its lead product candidates include GS010, an AAV2-based gene therapy that is currently undergoing Phase III clinical trials for Leber hereditary optic neuropathy caused by mutations in the ND4 gene, and GS030, which is in Phase I/II trials for retinitis pigmentosa and geographic atrophy associated with dry age-related macular degeneration. GenSight Biologics is also advancing other product candidates in preclinical development targeting various ophthalmic and neurodegenerative conditions.

Latent Labs is a pioneering AI laboratory specializing in programmable biology. It develops advanced generative AI models that capture the core principles of biology, empowering healthcare partners to create novel antibodies, optimize existing enzymes, and advance genetic engineering. This enables partners to gain unparalleled control over molecular biology, driving transformative advancements in health and sustainability.

Noema Pharma AG is a biotechnology company based in Basel, Switzerland, founded in 2019. The company focuses on developing innovative therapeutic products for orphan neurological disorders characterized by imbalanced neuronal networks. Its research and development efforts are dedicated to addressing disabling symptoms associated with conditions affecting the nervous system, such as Tuberous Sclerosis Complex, Trigeminal Neuralgia, and Tourette syndrome. By creating novel therapies, Noema Pharma aims to enhance the quality of life and improve patient outcomes for those suffering from these challenging disorders.

Meiogenix is a biotechnology company focused on developing innovative breeding technologies aimed at harnessing the untapped genetic diversity of various organisms. By modulating homologous recombination frequencies in eukaryotic cells, Meiogenix enhances natural biodiversity and facilitates the creation of new products. This approach is designed to help businesses tackle pressing global food and industrial challenges, ultimately contributing to sustainable solutions in these sectors.

Elicit Plant is an agro-biotech company focused on enhancing crops' resilience to water stress and developing innovative phytosterol-based solutions. By utilizing proprietary technology, the company aims to improve plant stress resistance and activate their natural defenses, addressing the global challenges posed by climate change in agriculture. Extensive field trials conducted across three continents have shown that Elicit Plant's biosolutions are effective, providing farmers with consistent and substantial returns on investment. Through its advancements, Elicit Plant seeks to lead the ecological transition in agriculture, ensuring that crops are better equipped to handle water shortages and contribute to sustainable farming practices.

Inventiva Pharma is a clinical-stage biopharmaceutical company based in France, dedicated to developing oral small molecule therapies aimed at addressing significant unmet medical needs in fibrosis, lysosomal storage disorders, and oncology. The company has established a robust pipeline supported by a proprietary discovery engine and a wholly-owned research and development facility. It possesses an extensive library of molecules and a team with considerable expertise in developing compounds that target nuclear receptors, transcription factors, and epigenetic modulation. Inventiva is advancing clinical candidates, including lanifibranor, which is being developed for non-alcoholic steatohepatitis (NASH), a condition currently lacking approved treatments. Additionally, the company is engaged in a variety of pre-clinical therapy programs, further strengthening its portfolio in the fields of oncology, fibrosis, and rare diseases.

Genespire is a biotechnology company dedicated to developing innovative gene therapies for patients suffering from genetic diseases, with a particular emphasis on primary immunodeficiencies and inherited metabolic disorders. The company specializes in creating therapies that utilize integration-defective lentiviral vectors combined with gene editing techniques. This approach allows for highly effective and adaptable targeted insertion of therapeutic genes into blood cells, providing patients with a range of tailored therapeutic options suited to their specific conditions. By focusing on transformative solutions, Genespire aims to significantly improve the lives of individuals affected by severe genetic disorders.

Micropep Technologies is an agricultural biotechnology company founded in 2016 and based in Toulouse, France. The company specializes in the development of non-GMO bioherbicides and biostimulants utilizing its innovative miPEP technology, which harnesses naturally-occurring micro-peptides to regulate gene expression and enhance plant growth. Micropep focuses on four key development programs: germination, flowering, growth, and weed control, aiming to improve agricultural yields while maintaining the integrity of plant DNA. By leveraging the potential of these biomimetic peptides, Micropep seeks to provide effective solutions for managing plant genetics and enhancing resistance to diseases, thereby supporting sustainable farming practices.

Cure51 is a company focused on advancing cancer treatment through the development of a clinical and molecular database. Its primary mission is to create a comprehensive database of cancer survivors, utilizing their unique biological characteristics to identify potential drug targets. By analyzing the biology of long-term cancer survivors, Cure51 aims to aid healthcare researchers in decoding genetic information derived from biopsies, blood tests, imaging, and other samples. This innovative approach seeks to accelerate drug discovery, ultimately contributing to the formulation of new and effective cancer therapies.

MISSION Therapeutics is a biotechnology company specializing in developing drugs that target the cellular process of deubiquitylation for the treatment of cancer and other diseases. Their focus is on developing small molecule drugs that selectively inhibit specific deubiquitylating enzymes (DUBs), which play crucial roles in regulating protein degradation and cellular processes. These drugs aim to intervene in disease mechanisms where DUB dysregulation is implicated, offering potential therapeutic benefits.

GenSight Biologics S.A. is a clinical-stage biotechnology company based in Paris, France, focused on the discovery and development of gene therapies for retinal degenerative diseases and neurodegenerative disorders of the central nervous system. Founded in 2012, the company utilizes innovative technologies, including mitochondrial targeting sequences and optogenetics, to develop treatments that aim to preserve or restore vision in patients with severe vision impairments. Its lead product candidates include GS010, an AAV2-based gene therapy that is currently undergoing Phase III clinical trials for Leber hereditary optic neuropathy caused by mutations in the ND4 gene, and GS030, which is in Phase I/II trials for retinitis pigmentosa and geographic atrophy associated with dry age-related macular degeneration. GenSight Biologics is also advancing other product candidates in preclinical development targeting various ophthalmic and neurodegenerative conditions.

DISCO Pharmaceuticals is a biotechnology company focused on advancing cancer treatment through its innovative surfaceome mapping platform. The firm specializes in large-scale surfaceome unlocking of cancer cells, utilizing transformative cell discovery technology to identify proteins and protein communities present on the surface of cancer cells. This scalable approach allows for the extraction of comprehensive target information that traditional proteomics, genome, or transcriptome sequencing methods cannot provide. By leveraging this technology, DISCO Pharmaceuticals aims to enable the development of cancer-selective therapies, potentially enhancing treatment efficacy while minimizing side effects for patients.

GlycoEra is a biotechnology research company focused on developing innovative therapeutics that target significant unmet medical needs in inflammatory and autoimmune diseases, as well as in immune-oncology. The company has established a proprietary platform that enables the creation of first-in-class biologics by assembling customized and highly homogeneous human glycans onto glycoproteins in a site-specific manner. This approach facilitates a deeper understanding of the role of glycans in human health and disease, positioning GlycoEra to contribute meaningfully to the advancement of novel treatment options in the healthcare sector.

Freya Biosciences is a clinical-stage women's health company headquartered in Copenhagen and Boston, specializing in the development of microbial immunotherapies. The company focuses on addressing significant unmet medical needs across various indications by utilizing a proprietary platform to engineer and manufacture live microbes. These engineered microbes are designed to be both safe and effective for human use, facilitating the creation of innovative treatments for a range of diseases.

GenSight Biologics S.A. is a clinical-stage biotechnology company based in Paris, France, focused on the discovery and development of gene therapies for retinal degenerative diseases and neurodegenerative disorders of the central nervous system. Founded in 2012, the company utilizes innovative technologies, including mitochondrial targeting sequences and optogenetics, to develop treatments that aim to preserve or restore vision in patients with severe vision impairments. Its lead product candidates include GS010, an AAV2-based gene therapy that is currently undergoing Phase III clinical trials for Leber hereditary optic neuropathy caused by mutations in the ND4 gene, and GS030, which is in Phase I/II trials for retinitis pigmentosa and geographic atrophy associated with dry age-related macular degeneration. GenSight Biologics is also advancing other product candidates in preclinical development targeting various ophthalmic and neurodegenerative conditions.

T-Therapeutics is a biopharmaceutical company focused on developing engineered soluble biologics for oncological and immunological applications. The company utilizes a proprietary T cell receptor (TCR) discovery platform based on a highly humanized mouse model, which allows access to TCRs for human antigens that are typically unavailable from human samples. This innovative approach enables the binding of specific peptide-MHC (pMHC) targets on cells, facilitating the recruitment of T cells to combat cancer or modulate immune responses. Through its advanced capabilities in mouse genome engineering, single-cell genomics, machine learning, and structural biology, T-Therapeutics aims to enhance the quality of life for patients suffering from chronic and infectious diseases. The company's culture emphasizes creativity and collaboration, fostering an environment conducive to groundbreaking research and development in the biopharmaceutical field.

Arzeda Corporation is a synthetic biology company based in Seattle, Washington, that focuses on the development and manufacture of enzymes and specialty chemical products. Established in 2008, Arzeda employs intelligent protein design technology, integrating physics-based methodologies with artificial intelligence to create innovative designer proteins and enzymes. Its product portfolio caters to various industries, including polymers, pharmaceuticals, and industrial chemicals, enabling clients to access high-performance solutions that also emphasize cost-effectiveness and sustainability.

Betteromics is a software-as-a-service (SaaS) platform tailored for the life sciences industry, utilizing advanced artificial intelligence and computational techniques to facilitate data analysis. The platform is structured as a Private SaaS within a Virtual Private Cloud, enabling seamless integration across various data sources. By providing a centralized and objective source of truth, Betteromics empowers professionals at all levels within an organization to create accurate and reliable data descriptions. The company was founded by seasoned executives from leading technology firms and is supported by a team of experts from academia, science, and technology sectors. Betteromics enables users to efficiently collect, process, and analyze complex multi-modal molecular datasets, leveraging machine learning and data science practices to enhance decision-making capabilities.

Sitryx Therapeutics is a biopharmaceutical company based in Oxford, United Kingdom, established in 2018. The company specializes in developing disease-modifying therapeutics that target immuno-oncology and immuno-inflammation by regulating cell metabolism. Through its innovative approach, Sitryx aims to correct and alter immune cell functions to inhibit tumor growth. Co-founded by a team of renowned scientists from both the United States and Europe, Sitryx is committed to advancing the field of immunometabolism. The company has a diverse pipeline of projects at various stages of drug discovery, supported by significant investments from a syndicate of specialist investors.

Inventiva Pharma is a clinical-stage biopharmaceutical company based in France, dedicated to developing oral small molecule therapies aimed at addressing significant unmet medical needs in fibrosis, lysosomal storage disorders, and oncology. The company has established a robust pipeline supported by a proprietary discovery engine and a wholly-owned research and development facility. It possesses an extensive library of molecules and a team with considerable expertise in developing compounds that target nuclear receptors, transcription factors, and epigenetic modulation. Inventiva is advancing clinical candidates, including lanifibranor, which is being developed for non-alcoholic steatohepatitis (NASH), a condition currently lacking approved treatments. Additionally, the company is engaged in a variety of pre-clinical therapy programs, further strengthening its portfolio in the fields of oncology, fibrosis, and rare diseases.

GenSight Biologics S.A. is a clinical-stage biotechnology company based in Paris, France, focused on the discovery and development of gene therapies for retinal degenerative diseases and neurodegenerative disorders of the central nervous system. Founded in 2012, the company utilizes innovative technologies, including mitochondrial targeting sequences and optogenetics, to develop treatments that aim to preserve or restore vision in patients with severe vision impairments. Its lead product candidates include GS010, an AAV2-based gene therapy that is currently undergoing Phase III clinical trials for Leber hereditary optic neuropathy caused by mutations in the ND4 gene, and GS030, which is in Phase I/II trials for retinitis pigmentosa and geographic atrophy associated with dry age-related macular degeneration. GenSight Biologics is also advancing other product candidates in preclinical development targeting various ophthalmic and neurodegenerative conditions.

Crescendo Biologics Limited is a clinical-stage biotechnology company based in Cambridge, United Kingdom, specializing in the development of innovative therapies for oncology and dermatology. The company focuses on creating multi-specific immune-oncology modulators and Humabody Drug Conjugates using its proprietary transgenic mouse platform. This technology allows for the in vivo maturation of human VH domains, optimizing their affinity and biophysical properties for therapeutic use. Crescendo Biologics aims to address critical challenges in generating high-affinity, soluble human VH antibody fragments, which are recognized for their potential as effective therapeutics. By leveraging its advanced platforms, the company is engaged in the product development of in-house targets as well as collaborations with other organizations to enhance the efficacy of cancer treatments. Founded in 2007 and originally known as Translocus Limited, Crescendo Biologics has established itself as a leader in the field of next-generation antibody therapeutics.

TISSIUM is a medical device company headquartered in Paris, France, focused on the development and commercialization of innovative biodegradable sealants and adhesives for surgical wound closure, particularly in minimally invasive procedures. The company's products are designed to be non-toxic, provide strong adhesion to tissues, and enable rapid wound closure in the body's dynamic environments. TISSIUM leverages advanced research and intellectual property from renowned laboratories, including those of Robert Langer at MIT and Jeff Karp at Brigham and Women’s Hospital. Its technology platform includes a proprietary family of fully biosynthetic, biomorphic, and programmable polymers, which are tailored for tissue reconstruction across various clinical applications. Founded in 2013, TISSIUM is supported by leading healthcare investors and aims to address unmet clinical needs through its groundbreaking approach to wound management.

Alia Therapeutics is focused on the development of next-generation gene-editing medicines aimed at curing rare genetic diseases. The company employs innovative CRISPR-based genome editing tools that allow for the correction of inborn genetic errors directly within patients' cells. By utilizing unique therapeutic approaches, Alia Therapeutics seeks to address genetic disorders at their root cause, enabling healthcare professionals to modify genomes effectively. Additionally, the company emphasizes the importance of safe and efficient delivery methods for these gene-editing solutions to target cells, positioning itself at the forefront of advancements in the treatment of genetic diseases.

Noema Pharma AG is a biotechnology company based in Basel, Switzerland, founded in 2019. The company focuses on developing innovative therapeutic products for orphan neurological disorders characterized by imbalanced neuronal networks. Its research and development efforts are dedicated to addressing disabling symptoms associated with conditions affecting the nervous system, such as Tuberous Sclerosis Complex, Trigeminal Neuralgia, and Tourette syndrome. By creating novel therapies, Noema Pharma aims to enhance the quality of life and improve patient outcomes for those suffering from these challenging disorders.

Chroma Medicine is a genomic medicine company founded in 2021 and based in Cambridge, Massachusetts, specializing in epigenetic editing. The company is pioneering a new class of genomic therapies aimed at revolutionizing the treatment of genetically driven diseases. By utilizing epigenetics, which is the natural mechanism for gene regulation, Chroma Medicine develops programmable epigenetic editors that target specific genes and modulate chromatin conformation. This innovative approach enables healthcare providers to achieve precise control of gene expression, offering a promising therapeutic option for conditions linked to genetic anomalies.

Abivax is a clinical-stage biotechnology company based in France, dedicated to developing innovative therapeutics that leverage the body's natural immune mechanisms to treat patients with autoimmune diseases, viral infections, and cancer. The company's primary focus is on chronic inflammatory diseases, particularly inflammatory bowel diseases such as ulcerative colitis and Crohn's disease. Abivax is currently evaluating its leading drug candidate, obefazimod, in Phase 3 clinical trials aimed at addressing moderately to severely active ulcerative colitis. Through its drug development platforms, Abivax strives to deliver novel and effective treatments to patients with significant unmet medical needs in these therapeutic areas.

Amolyt Pharma is a clinical-stage biotechnology company focused on developing peptide-based therapies for rare endocrine and metabolic disorders. The company is advancing several programs, including AZP-3601, a parathyroid hormone analog aimed at treating hypoparathyroidism by maintaining stable calcium levels in the blood. Additionally, Amolyt Pharma is developing AZP-3404, a peptide with a novel mechanism of action designed to restore fat and glucose metabolism. Through its innovative approaches, the company aims to provide effective solutions for patients suffering from critical and rare metabolic conditions.

EnginZyme AB is a biotechnology company based in Stockholm, Sweden, founded in 2014. It specializes in biocatalysis and cell-free synthetic biology, providing sustainable alternatives to traditional materials such as plastics, nylons, and rubbers. EnginZyme's innovative platform utilizes enzymes to facilitate the green manufacturing of products essential to various industries, including pharmaceuticals, food, chemicals, flavors, and fragrances. By replacing fossil-based manufacturing processes with its patented cell-free technology, the company aims to contribute to climate change mitigation and promote sustainable biomanufacturing practices. EnginZyme has garnered recognition as a Global Cleantech 100 company and has been acknowledged as a Technology Pioneer by the World Economic Forum, underscoring its commitment to advancing green chemistry across multiple sectors.

Mablink Bioscience is a biotechnology company focused on developing a new class of cancer therapies known as Antibody Drug Conjugates (ADCs). The company specializes in designing homogeneous, plasma-stable ADCs that maintain their original pharmacological properties while achieving a high drug-to-antibody ratio (DAR). This innovative approach aims to provide healthcare professionals with enhanced treatment options for cancer patients, ultimately improving therapeutic outcomes.

Abivax is a clinical-stage biotechnology company based in France, dedicated to developing innovative therapeutics that leverage the body's natural immune mechanisms to treat patients with autoimmune diseases, viral infections, and cancer. The company's primary focus is on chronic inflammatory diseases, particularly inflammatory bowel diseases such as ulcerative colitis and Crohn's disease. Abivax is currently evaluating its leading drug candidate, obefazimod, in Phase 3 clinical trials aimed at addressing moderately to severely active ulcerative colitis. Through its drug development platforms, Abivax strives to deliver novel and effective treatments to patients with significant unmet medical needs in these therapeutic areas.

F2G Ltd is a biotechnology company focused on developing innovative therapies for serious fungal infections. Founded in 1998 and based in Manchester, United Kingdom, F2G primarily works on its F3 series of anti-mold compounds, specifically targeting antifungal agents against Aspergillus and other filamentous molds. Utilizing proprietary genomics technology known as MycoBank, the company identifies essential gene targets in fungi, which informs its drug development process. F2G has diversified its approach to include chemistry-driven discovery, leveraging a strong development team to advance its patented compounds. The company's efforts aim to address difficult-to-treat fungal pathogens that pose significant mortality risks, particularly for immunocompromised patients, thereby enhancing treatment options in the pharmaceutical industry.

Biosyntia ApS, established in 2012 and based in Hørsholm, Denmark, is a biotechnology company specializing in the development of biocatalysts for the fermentation of fine chemicals. It leverages synthetic biology and metabolic engineering to create biocatalysts at an accelerated pace and efficiency, using a patent-pending high-throughput screening technology. By enabling the production of complex chemical compounds, such as flavors, fragrances, APIs, and pigments, through fermentation, Biosyntia facilitates more sustainable and cost-effective manufacturing processes for its industrial partners. The company operates from the Novo Nordisk Foundation Center for Biosustainability in Hørsholm.

Micropep Technologies is an agricultural biotechnology company founded in 2016 and based in Toulouse, France. The company specializes in the development of non-GMO bioherbicides and biostimulants utilizing its innovative miPEP technology, which harnesses naturally-occurring micro-peptides to regulate gene expression and enhance plant growth. Micropep focuses on four key development programs: germination, flowering, growth, and weed control, aiming to improve agricultural yields while maintaining the integrity of plant DNA. By leveraging the potential of these biomimetic peptides, Micropep seeks to provide effective solutions for managing plant genetics and enhancing resistance to diseases, thereby supporting sustainable farming practices.

Elicit Plant is an agro-biotech company focused on enhancing crops' resilience to water stress and developing innovative phytosterol-based solutions. By utilizing proprietary technology, the company aims to improve plant stress resistance and activate their natural defenses, addressing the global challenges posed by climate change in agriculture. Extensive field trials conducted across three continents have shown that Elicit Plant's biosolutions are effective, providing farmers with consistent and substantial returns on investment. Through its advancements, Elicit Plant seeks to lead the ecological transition in agriculture, ensuring that crops are better equipped to handle water shortages and contribute to sustainable farming practices.

Meiogenix is a biotechnology company focused on developing innovative breeding technologies aimed at harnessing the untapped genetic diversity of various organisms. By modulating homologous recombination frequencies in eukaryotic cells, Meiogenix enhances natural biodiversity and facilitates the creation of new products. This approach is designed to help businesses tackle pressing global food and industrial challenges, ultimately contributing to sustainable solutions in these sectors.

DMC Biotechnologies, Inc. is a biotechnology company based in Boulder, Colorado, that specializes in the development of bio-based products through microbial fermentation technology. Founded in 2014, the company focuses on engineering microbial hosts to produce a range of specialty chemicals, flavors, fragrances, nutraceuticals, natural products, and pharmaceuticals. DMC Biotechnologies employs its proprietary Dynamic Metabolic Control technology to enhance production efficiency, thereby reducing costs and accelerating the timeline from discovery to commercial performance. The company's innovative approach supports sustainability by utilizing lower energy and resource inputs in the manufacturing process.

Synthace Limited is a London-based company specializing in the development and operation of software solutions for various industries, including health, pharmaceuticals, food, energy, agri-science, industrial biotechnology, and manufacturing. The company offers Antha, a cloud-based platform designed to automate and enhance biological processes. This platform allows life science researchers to digitize experiments from start to finish, enabling them to design, simulate, and execute reproducible experiments with minimal training. Antha facilitates the integration of experimental data and metadata in a streamlined manner, making it easier for scientists to manage their workflows and increasing the scientific value of their research. Synthace's technology empowers researchers to conduct complex experiments without the need for coding, thereby expanding the possibilities of laboratory experimentation. Founded in 2011, Synthace also has a presence in Cambridge, Massachusetts, and maintains a strategic partnership with Microsoft.

Home Biosciences is a European venture builder focused on the biotechnology sector. The company is designed to facilitate scientific breakthroughs through its asset-centric operating model. By providing funding and operational support, Home Biosciences allows project teams to concentrate fully on their research and development efforts. This approach enables the creation of sustainable biotech ventures by assembling the necessary expertise and organizational structure, thereby fostering innovation and growth in the industry.

GlycoEra is a biotechnology research company focused on developing innovative therapeutics that target significant unmet medical needs in inflammatory and autoimmune diseases, as well as in immune-oncology. The company has established a proprietary platform that enables the creation of first-in-class biologics by assembling customized and highly homogeneous human glycans onto glycoproteins in a site-specific manner. This approach facilitates a deeper understanding of the role of glycans in human health and disease, positioning GlycoEra to contribute meaningfully to the advancement of novel treatment options in the healthcare sector.

Sphere Fluidics Limited is a life sciences company focused on developing innovative technologies for single-cell analysis and characterization. The company offers unique products and collaborative research and development services that aid in the discovery of new cell strains and molecules. Its cell analysis systems facilitate the screening and isolation of rare and valuable biological variants, catering to various applications in research, therapeutic development, bioproduction, and diagnostics. By streamlining these processes, Sphere Fluidics enables clients to reduce costs and time, thereby accelerating advancements in biological and biopharmaceutical discovery.

Mozart Therapeutics is a biotechnology startup dedicated to developing innovative therapies for autoimmune and inflammatory diseases. The company specializes in creating disease-modifying CD8 T cell modulators, leveraging a unique regulatory CD8 T cell network to target a specific subset of T lymphocytes. These modulators aim to restore immune balance and mitigate the damage caused by autoreactive and pathogenic immune responses. By focusing on first-in-class CD8 Treg modulators, Mozart Therapeutics seeks to delay the onset and improve the management of various autoimmune disorders, thereby providing healthcare professionals with advanced treatment options for their patients.

Leucid Bio is an innovative biotech company focused on developing advanced cell therapies for refractory cancers, particularly solid tumors. Founded to leverage two decades of research from King's College London in the CAR-T field, Leucid Bio is led by a team with extensive scientific and commercial expertise. The company specializes in creating novel CAR T-cell therapies designed to deliver improved and more durable responses compared to earlier generations, thereby enhancing treatment outcomes for patients who have exhausted other options. Through its ongoing collaboration with King's College, Leucid Bio has exclusive access to a wealth of scientific, clinical, and manufacturing resources, positioning it at the forefront of immuno-oncology advancements.

TISSIUM is a medical device company headquartered in Paris, France, focused on the development and commercialization of innovative biodegradable sealants and adhesives for surgical wound closure, particularly in minimally invasive procedures. The company's products are designed to be non-toxic, provide strong adhesion to tissues, and enable rapid wound closure in the body's dynamic environments. TISSIUM leverages advanced research and intellectual property from renowned laboratories, including those of Robert Langer at MIT and Jeff Karp at Brigham and Women’s Hospital. Its technology platform includes a proprietary family of fully biosynthetic, biomorphic, and programmable polymers, which are tailored for tissue reconstruction across various clinical applications. Founded in 2013, TISSIUM is supported by leading healthcare investors and aims to address unmet clinical needs through its groundbreaking approach to wound management.

Artios Pharma Limited is a biotechnology company based in Cambridge, United Kingdom, that specializes in developing innovative cancer treatments targeting DNA damage response (DDR) pathways. Founded in 2016, the company is dedicated to creating first-in-class therapies that selectively kill cancer cells by exploiting their reliance on DDR mechanisms. Artios’ product pipeline includes a range of promising candidates, such as a therapy that targets DNA polymerase theta, a protein involved in DNA repair processes, and another program focusing on a novel DDR target. The company collaborates with prominent research organizations, including Cancer Research Technology, to enhance its development efforts and leverage expertise in DNA repair. Artios is led by a skilled team with extensive experience in drug discovery, positioning it to advance its next-generation DDR programs and contribute significantly to the field of cancer treatment.

Muna Therapeutics is a private biopharmaceutical company focused on discovering and developing therapies aimed at slowing or halting the progression of neurodegenerative diseases such as Parkinson's, Alzheimer's, Frontotemporal Dementia, and Multiple Sclerosis. The company is dedicated to identifying innovative medicines that preserve cognitive functions and enhance resilience in individuals affected by these conditions. By prioritizing the development of suitable therapeutics, Muna Therapeutics aims to improve recovery outcomes for patients suffering from neurodegenerative diseases.

Micropep Technologies is an agricultural biotechnology company founded in 2016 and based in Toulouse, France. The company specializes in the development of non-GMO bioherbicides and biostimulants utilizing its innovative miPEP technology, which harnesses naturally-occurring micro-peptides to regulate gene expression and enhance plant growth. Micropep focuses on four key development programs: germination, flowering, growth, and weed control, aiming to improve agricultural yields while maintaining the integrity of plant DNA. By leveraging the potential of these biomimetic peptides, Micropep seeks to provide effective solutions for managing plant genetics and enhancing resistance to diseases, thereby supporting sustainable farming practices.

Alia Therapeutics is focused on the development of next-generation gene-editing medicines aimed at curing rare genetic diseases. The company employs innovative CRISPR-based genome editing tools that allow for the correction of inborn genetic errors directly within patients' cells. By utilizing unique therapeutic approaches, Alia Therapeutics seeks to address genetic disorders at their root cause, enabling healthcare professionals to modify genomes effectively. Additionally, the company emphasizes the importance of safe and efficient delivery methods for these gene-editing solutions to target cells, positioning itself at the forefront of advancements in the treatment of genetic diseases.

Mnemo Therapeutics is a biotechnology company focused on developing immune-based therapies, particularly cell therapies, aimed at providing accessible cures for solid tumors and blood cancers. The company's EnfiniT platform serves as an advanced drug discovery engine that harnesses a specific class of antigens along with various technologies to target tumorous epitopes found across multiple cancer types. By utilizing epigenetic variation and precision genetic engineering technologies, Mnemo Therapeutics creates allogeneic treatments designed to effectively address and overcome these diseases, advancing the field of cancer treatment.

Noema Pharma AG is a biotechnology company based in Basel, Switzerland, founded in 2019. The company focuses on developing innovative therapeutic products for orphan neurological disorders characterized by imbalanced neuronal networks. Its research and development efforts are dedicated to addressing disabling symptoms associated with conditions affecting the nervous system, such as Tuberous Sclerosis Complex, Trigeminal Neuralgia, and Tourette syndrome. By creating novel therapies, Noema Pharma aims to enhance the quality of life and improve patient outcomes for those suffering from these challenging disorders.

Catamaran Bio, Inc. is a biotechnology company focused on developing allogeneic CAR-NK immune cell therapies for the treatment of solid tumors and other cancers. Founded in 2019 and based in Cambridge, Massachusetts, the company utilizes its Tailwind platform to engineer, expand, and process natural killer (NK) cells into off-the-shelf CAR-NK cell therapy products. By leveraging genetic engineering, Catamaran Bio aims to address significant unmet medical needs in cancer treatment, providing transformative therapies for patients.

GenSight Biologics S.A. is a clinical-stage biotechnology company based in Paris, France, focused on the discovery and development of gene therapies for retinal degenerative diseases and neurodegenerative disorders of the central nervous system. Founded in 2012, the company utilizes innovative technologies, including mitochondrial targeting sequences and optogenetics, to develop treatments that aim to preserve or restore vision in patients with severe vision impairments. Its lead product candidates include GS010, an AAV2-based gene therapy that is currently undergoing Phase III clinical trials for Leber hereditary optic neuropathy caused by mutations in the ND4 gene, and GS030, which is in Phase I/II trials for retinitis pigmentosa and geographic atrophy associated with dry age-related macular degeneration. GenSight Biologics is also advancing other product candidates in preclinical development targeting various ophthalmic and neurodegenerative conditions.

Polyneuron Pharmaceuticals AG is a biopharmaceutical company based in Basel, Switzerland, focused on developing innovative therapeutics for the treatment of autoimmune disorders. Founded in 2014, the company specializes in creating drugs to target specific autoimmune conditions, including PN-1007 for anti-MAG neuropathy, PN-1018 for multifocal motor neuropathy, and PN-032 and PN-056 for ABO-incompatible transplantation. Polyneuron's therapeutic approach employs biodegradable glycopolymers that selectively eliminate pathological autoantibodies, preserving the overall integrity of the immune system. This technology, referred to as Antibody-Catch, aims to provide safe and effective treatment options for patients suffering from autoimmune diseases affecting the peripheral nervous system, particularly those involving autoantibodies against carbohydrate epitopes.

MISSION Therapeutics is a biotechnology company specializing in developing drugs that target the cellular process of deubiquitylation for the treatment of cancer and other diseases. Their focus is on developing small molecule drugs that selectively inhibit specific deubiquitylating enzymes (DUBs), which play crucial roles in regulating protein degradation and cellular processes. These drugs aim to intervene in disease mechanisms where DUB dysregulation is implicated, offering potential therapeutic benefits.

NodThera Limited is a biotechnology company engaged in the research and development of novel inhibitors targeting the NLRP3 inflammasome to address various inflammatory and neuroinflammatory diseases. Founded in 2016 and headquartered in Little Chesterford, United Kingdom, with additional facilities in Seattle, Washington, and a corporate office in Lexington, Massachusetts, NodThera focuses on creating therapies for conditions such as arthritis, atherosclerosis, Alzheimer’s disease, diabetes, and certain cancers. The company's drug development pipeline includes potent and selective NLRP3 inflammasome inhibitors designed to reduce pro-inflammatory cytokines associated with chronic inflammation, thereby enhancing treatment options for patients suffering from these chronic diseases.

Genespire is a biotechnology company dedicated to developing innovative gene therapies for patients suffering from genetic diseases, with a particular emphasis on primary immunodeficiencies and inherited metabolic disorders. The company specializes in creating therapies that utilize integration-defective lentiviral vectors combined with gene editing techniques. This approach allows for highly effective and adaptable targeted insertion of therapeutic genes into blood cells, providing patients with a range of tailored therapeutic options suited to their specific conditions. By focusing on transformative solutions, Genespire aims to significantly improve the lives of individuals affected by severe genetic disorders.

EnginZyme AB is a biotechnology company based in Stockholm, Sweden, founded in 2014. It specializes in biocatalysis and cell-free synthetic biology, providing sustainable alternatives to traditional materials such as plastics, nylons, and rubbers. EnginZyme's innovative platform utilizes enzymes to facilitate the green manufacturing of products essential to various industries, including pharmaceuticals, food, chemicals, flavors, and fragrances. By replacing fossil-based manufacturing processes with its patented cell-free technology, the company aims to contribute to climate change mitigation and promote sustainable biomanufacturing practices. EnginZyme has garnered recognition as a Global Cleantech 100 company and has been acknowledged as a Technology Pioneer by the World Economic Forum, underscoring its commitment to advancing green chemistry across multiple sectors.

Inventiva Pharma is a clinical-stage biopharmaceutical company based in France, dedicated to developing oral small molecule therapies aimed at addressing significant unmet medical needs in fibrosis, lysosomal storage disorders, and oncology. The company has established a robust pipeline supported by a proprietary discovery engine and a wholly-owned research and development facility. It possesses an extensive library of molecules and a team with considerable expertise in developing compounds that target nuclear receptors, transcription factors, and epigenetic modulation. Inventiva is advancing clinical candidates, including lanifibranor, which is being developed for non-alcoholic steatohepatitis (NASH), a condition currently lacking approved treatments. Additionally, the company is engaged in a variety of pre-clinical therapy programs, further strengthening its portfolio in the fields of oncology, fibrosis, and rare diseases.

Chroma Medicine is a genomic medicine company founded in 2021 and based in Cambridge, Massachusetts, specializing in epigenetic editing. The company is pioneering a new class of genomic therapies aimed at revolutionizing the treatment of genetically driven diseases. By utilizing epigenetics, which is the natural mechanism for gene regulation, Chroma Medicine develops programmable epigenetic editors that target specific genes and modulate chromatin conformation. This innovative approach enables healthcare providers to achieve precise control of gene expression, offering a promising therapeutic option for conditions linked to genetic anomalies.

GenSight Biologics S.A. is a clinical-stage biotechnology company based in Paris, France, focused on the discovery and development of gene therapies for retinal degenerative diseases and neurodegenerative disorders of the central nervous system. Founded in 2012, the company utilizes innovative technologies, including mitochondrial targeting sequences and optogenetics, to develop treatments that aim to preserve or restore vision in patients with severe vision impairments. Its lead product candidates include GS010, an AAV2-based gene therapy that is currently undergoing Phase III clinical trials for Leber hereditary optic neuropathy caused by mutations in the ND4 gene, and GS030, which is in Phase I/II trials for retinitis pigmentosa and geographic atrophy associated with dry age-related macular degeneration. GenSight Biologics is also advancing other product candidates in preclinical development targeting various ophthalmic and neurodegenerative conditions.

DMC Biotechnologies, Inc. is a biotechnology company based in Boulder, Colorado, that specializes in the development of bio-based products through microbial fermentation technology. Founded in 2014, the company focuses on engineering microbial hosts to produce a range of specialty chemicals, flavors, fragrances, nutraceuticals, natural products, and pharmaceuticals. DMC Biotechnologies employs its proprietary Dynamic Metabolic Control technology to enhance production efficiency, thereby reducing costs and accelerating the timeline from discovery to commercial performance. The company's innovative approach supports sustainability by utilizing lower energy and resource inputs in the manufacturing process.

TISSIUM is a medical device company headquartered in Paris, France, focused on the development and commercialization of innovative biodegradable sealants and adhesives for surgical wound closure, particularly in minimally invasive procedures. The company's products are designed to be non-toxic, provide strong adhesion to tissues, and enable rapid wound closure in the body's dynamic environments. TISSIUM leverages advanced research and intellectual property from renowned laboratories, including those of Robert Langer at MIT and Jeff Karp at Brigham and Women’s Hospital. Its technology platform includes a proprietary family of fully biosynthetic, biomorphic, and programmable polymers, which are tailored for tissue reconstruction across various clinical applications. Founded in 2013, TISSIUM is supported by leading healthcare investors and aims to address unmet clinical needs through its groundbreaking approach to wound management.

Inventiva Pharma is a clinical-stage biopharmaceutical company based in France, dedicated to developing oral small molecule therapies aimed at addressing significant unmet medical needs in fibrosis, lysosomal storage disorders, and oncology. The company has established a robust pipeline supported by a proprietary discovery engine and a wholly-owned research and development facility. It possesses an extensive library of molecules and a team with considerable expertise in developing compounds that target nuclear receptors, transcription factors, and epigenetic modulation. Inventiva is advancing clinical candidates, including lanifibranor, which is being developed for non-alcoholic steatohepatitis (NASH), a condition currently lacking approved treatments. Additionally, the company is engaged in a variety of pre-clinical therapy programs, further strengthening its portfolio in the fields of oncology, fibrosis, and rare diseases.

Abivax is a clinical-stage biotechnology company based in France, dedicated to developing innovative therapeutics that leverage the body's natural immune mechanisms to treat patients with autoimmune diseases, viral infections, and cancer. The company's primary focus is on chronic inflammatory diseases, particularly inflammatory bowel diseases such as ulcerative colitis and Crohn's disease. Abivax is currently evaluating its leading drug candidate, obefazimod, in Phase 3 clinical trials aimed at addressing moderately to severely active ulcerative colitis. Through its drug development platforms, Abivax strives to deliver novel and effective treatments to patients with significant unmet medical needs in these therapeutic areas.

DNA Script is a pioneering company in the field of DNA synthesis, focused on enhancing life sciences and human health through innovative technology. It has developed the SYNTAX, the world's first benchtop DNA printer, which allows laboratories to produce synthetic oligonucleotides using a novel enzymatic process. This method employs natural enzymes for nucleic acid synthesis, enabling rapid and efficient production of critical genomic experimental precursors. By providing greater control over workflow and accelerating access to results, DNA Script supports researchers in advancing experiments and developing new therapeutics effectively.

Twentyeight-Seven Therapeutics is a developer of microRNAs designed to target regulatory proteins.The company's modulating RNA which are short non-coding RNAs that inhibit target gene expression by suppressing mRNA translation and promoting mRNA decay and develop small molecules that can modulate levels of miRNAs by targeting proteins that interact with these miRNAs, enabling users to target miRNAs are directly involved in cancer initiation, progression, and metastasis.

Polyneuron Pharmaceuticals AG is a biopharmaceutical company based in Basel, Switzerland, focused on developing innovative therapeutics for the treatment of autoimmune disorders. Founded in 2014, the company specializes in creating drugs to target specific autoimmune conditions, including PN-1007 for anti-MAG neuropathy, PN-1018 for multifocal motor neuropathy, and PN-032 and PN-056 for ABO-incompatible transplantation. Polyneuron's therapeutic approach employs biodegradable glycopolymers that selectively eliminate pathological autoantibodies, preserving the overall integrity of the immune system. This technology, referred to as Antibody-Catch, aims to provide safe and effective treatment options for patients suffering from autoimmune diseases affecting the peripheral nervous system, particularly those involving autoantibodies against carbohydrate epitopes.

GenSight Biologics S.A. is a clinical-stage biotechnology company based in Paris, France, focused on the discovery and development of gene therapies for retinal degenerative diseases and neurodegenerative disorders of the central nervous system. Founded in 2012, the company utilizes innovative technologies, including mitochondrial targeting sequences and optogenetics, to develop treatments that aim to preserve or restore vision in patients with severe vision impairments. Its lead product candidates include GS010, an AAV2-based gene therapy that is currently undergoing Phase III clinical trials for Leber hereditary optic neuropathy caused by mutations in the ND4 gene, and GS030, which is in Phase I/II trials for retinitis pigmentosa and geographic atrophy associated with dry age-related macular degeneration. GenSight Biologics is also advancing other product candidates in preclinical development targeting various ophthalmic and neurodegenerative conditions.

Sitryx Therapeutics is a biopharmaceutical company based in Oxford, United Kingdom, established in 2018. The company specializes in developing disease-modifying therapeutics that target immuno-oncology and immuno-inflammation by regulating cell metabolism. Through its innovative approach, Sitryx aims to correct and alter immune cell functions to inhibit tumor growth. Co-founded by a team of renowned scientists from both the United States and Europe, Sitryx is committed to advancing the field of immunometabolism. The company has a diverse pipeline of projects at various stages of drug discovery, supported by significant investments from a syndicate of specialist investors.

NodThera Limited is a biotechnology company engaged in the research and development of novel inhibitors targeting the NLRP3 inflammasome to address various inflammatory and neuroinflammatory diseases. Founded in 2016 and headquartered in Little Chesterford, United Kingdom, with additional facilities in Seattle, Washington, and a corporate office in Lexington, Massachusetts, NodThera focuses on creating therapies for conditions such as arthritis, atherosclerosis, Alzheimer’s disease, diabetes, and certain cancers. The company's drug development pipeline includes potent and selective NLRP3 inflammasome inhibitors designed to reduce pro-inflammatory cytokines associated with chronic inflammation, thereby enhancing treatment options for patients suffering from these chronic diseases.

Biosyntia ApS, established in 2012 and based in Hørsholm, Denmark, is a biotechnology company specializing in the development of biocatalysts for the fermentation of fine chemicals. It leverages synthetic biology and metabolic engineering to create biocatalysts at an accelerated pace and efficiency, using a patent-pending high-throughput screening technology. By enabling the production of complex chemical compounds, such as flavors, fragrances, APIs, and pigments, through fermentation, Biosyntia facilitates more sustainable and cost-effective manufacturing processes for its industrial partners. The company operates from the Novo Nordisk Foundation Center for Biosustainability in Hørsholm.

Crescendo Biologics Limited is a clinical-stage biotechnology company based in Cambridge, United Kingdom, specializing in the development of innovative therapies for oncology and dermatology. The company focuses on creating multi-specific immune-oncology modulators and Humabody Drug Conjugates using its proprietary transgenic mouse platform. This technology allows for the in vivo maturation of human VH domains, optimizing their affinity and biophysical properties for therapeutic use. Crescendo Biologics aims to address critical challenges in generating high-affinity, soluble human VH antibody fragments, which are recognized for their potential as effective therapeutics. By leveraging its advanced platforms, the company is engaged in the product development of in-house targets as well as collaborations with other organizations to enhance the efficacy of cancer treatments. Founded in 2007 and originally known as Translocus Limited, Crescendo Biologics has established itself as a leader in the field of next-generation antibody therapeutics.

Inventiva Pharma is a clinical-stage biopharmaceutical company based in France, dedicated to developing oral small molecule therapies aimed at addressing significant unmet medical needs in fibrosis, lysosomal storage disorders, and oncology. The company has established a robust pipeline supported by a proprietary discovery engine and a wholly-owned research and development facility. It possesses an extensive library of molecules and a team with considerable expertise in developing compounds that target nuclear receptors, transcription factors, and epigenetic modulation. Inventiva is advancing clinical candidates, including lanifibranor, which is being developed for non-alcoholic steatohepatitis (NASH), a condition currently lacking approved treatments. Additionally, the company is engaged in a variety of pre-clinical therapy programs, further strengthening its portfolio in the fields of oncology, fibrosis, and rare diseases.

Micropep Technologies is an agricultural biotechnology company founded in 2016 and based in Toulouse, France. The company specializes in the development of non-GMO bioherbicides and biostimulants utilizing its innovative miPEP technology, which harnesses naturally-occurring micro-peptides to regulate gene expression and enhance plant growth. Micropep focuses on four key development programs: germination, flowering, growth, and weed control, aiming to improve agricultural yields while maintaining the integrity of plant DNA. By leveraging the potential of these biomimetic peptides, Micropep seeks to provide effective solutions for managing plant genetics and enhancing resistance to diseases, thereby supporting sustainable farming practices.

Mironid Limited is a biotechnology company based in Newhouse, United Kingdom, that specializes in drug discovery and development. Founded in 2014, Mironid focuses on creating innovative drug candidate molecules that modulate key cell signaling proteins to address degenerative kidney diseases, chronic inflammatory diseases, and cancer. The company's pipeline includes unique compounds designed to treat these conditions, utilizing a Physiology Mirroring Approach that aligns drug target environments with those found in living cells. Mironid aims to identify and validate novel drug targets, particularly in areas with significant unmet medical needs, by leveraging advanced technologies to streamline and enhance the drug discovery process. Through its dedicated efforts, Mironid seeks to develop differentiated therapies that improve patient health and quality of life.

Synthace Limited is a London-based company specializing in the development and operation of software solutions for various industries, including health, pharmaceuticals, food, energy, agri-science, industrial biotechnology, and manufacturing. The company offers Antha, a cloud-based platform designed to automate and enhance biological processes. This platform allows life science researchers to digitize experiments from start to finish, enabling them to design, simulate, and execute reproducible experiments with minimal training. Antha facilitates the integration of experimental data and metadata in a streamlined manner, making it easier for scientists to manage their workflows and increasing the scientific value of their research. Synthace's technology empowers researchers to conduct complex experiments without the need for coding, thereby expanding the possibilities of laboratory experimentation. Founded in 2011, Synthace also has a presence in Cambridge, Massachusetts, and maintains a strategic partnership with Microsoft.

DNA Script is a pioneering company in the field of DNA synthesis, focused on enhancing life sciences and human health through innovative technology. It has developed the SYNTAX, the world's first benchtop DNA printer, which allows laboratories to produce synthetic oligonucleotides using a novel enzymatic process. This method employs natural enzymes for nucleic acid synthesis, enabling rapid and efficient production of critical genomic experimental precursors. By providing greater control over workflow and accelerating access to results, DNA Script supports researchers in advancing experiments and developing new therapeutics effectively.

DNA Script is a pioneering company in the field of DNA synthesis, focused on enhancing life sciences and human health through innovative technology. It has developed the SYNTAX, the world's first benchtop DNA printer, which allows laboratories to produce synthetic oligonucleotides using a novel enzymatic process. This method employs natural enzymes for nucleic acid synthesis, enabling rapid and efficient production of critical genomic experimental precursors. By providing greater control over workflow and accelerating access to results, DNA Script supports researchers in advancing experiments and developing new therapeutics effectively.

TISSIUM is a medical device company headquartered in Paris, France, focused on the development and commercialization of innovative biodegradable sealants and adhesives for surgical wound closure, particularly in minimally invasive procedures. The company's products are designed to be non-toxic, provide strong adhesion to tissues, and enable rapid wound closure in the body's dynamic environments. TISSIUM leverages advanced research and intellectual property from renowned laboratories, including those of Robert Langer at MIT and Jeff Karp at Brigham and Women’s Hospital. Its technology platform includes a proprietary family of fully biosynthetic, biomorphic, and programmable polymers, which are tailored for tissue reconstruction across various clinical applications. Founded in 2013, TISSIUM is supported by leading healthcare investors and aims to address unmet clinical needs through its groundbreaking approach to wound management.

MISSION Therapeutics is a biotechnology company specializing in developing drugs that target the cellular process of deubiquitylation for the treatment of cancer and other diseases. Their focus is on developing small molecule drugs that selectively inhibit specific deubiquitylating enzymes (DUBs), which play crucial roles in regulating protein degradation and cellular processes. These drugs aim to intervene in disease mechanisms where DUB dysregulation is implicated, offering potential therapeutic benefits.

ENYO Pharma SA is a clinical-stage biopharmaceutical company based in Lyon, France, founded in 2014 by scientists from the Infectiology Research Center. The company focuses on drug discovery and development for the treatment of acute and chronic viral infections, utilizing a unique platform to identify intracellular therapeutic targets and molecules. ENYO Pharma is developing a pipeline of drug candidates addressing various indications, including hepatitis B virus, nonalcoholic steatohepatitis, and oncology. Its lead compound, EYP001, is designed to modulate specific nuclear receptors, aiming to reduce viral reservoirs and inhibit harmful viral protein expression. The company is also advancing EYP002 through preclinical studies. ENYO Pharma collaborates closely with established research institutions and aims to conduct its molecules into Phase II clinical trials, striving to become a global leader in antiviral therapeutics.

Synthace Limited is a London-based company specializing in the development and operation of software solutions for various industries, including health, pharmaceuticals, food, energy, agri-science, industrial biotechnology, and manufacturing. The company offers Antha, a cloud-based platform designed to automate and enhance biological processes. This platform allows life science researchers to digitize experiments from start to finish, enabling them to design, simulate, and execute reproducible experiments with minimal training. Antha facilitates the integration of experimental data and metadata in a streamlined manner, making it easier for scientists to manage their workflows and increasing the scientific value of their research. Synthace's technology empowers researchers to conduct complex experiments without the need for coding, thereby expanding the possibilities of laboratory experimentation. Founded in 2011, Synthace also has a presence in Cambridge, Massachusetts, and maintains a strategic partnership with Microsoft.

Crescendo Biologics Limited is a clinical-stage biotechnology company based in Cambridge, United Kingdom, specializing in the development of innovative therapies for oncology and dermatology. The company focuses on creating multi-specific immune-oncology modulators and Humabody Drug Conjugates using its proprietary transgenic mouse platform. This technology allows for the in vivo maturation of human VH domains, optimizing their affinity and biophysical properties for therapeutic use. Crescendo Biologics aims to address critical challenges in generating high-affinity, soluble human VH antibody fragments, which are recognized for their potential as effective therapeutics. By leveraging its advanced platforms, the company is engaged in the product development of in-house targets as well as collaborations with other organizations to enhance the efficacy of cancer treatments. Founded in 2007 and originally known as Translocus Limited, Crescendo Biologics has established itself as a leader in the field of next-generation antibody therapeutics.

NuCana plc is a UK-based, clinical-stage biopharmaceutical company dedicated to developing innovative cancer treatments. It specializes in transforming widely-used chemotherapy agents into more effective and safer medicines using its proprietary ProTide technology. NuCana's pipeline includes Acelarin, in Phase III trials for biliary tract and metastatic pancreatic cancers, and NUC-3373 & NUC-7738, in Phase I trials for advanced solid tumors. The company collaborates with academic institutions for research and licensing agreements. NuCana was established in 1997 and is headquartered in Edinburgh, with a focus on the U.S. market.

ProQR Therapeutics N.V. is a biopharmaceutical company based in Leiden, the Netherlands, focused on the discovery and development of RNA-based therapeutics for genetic disorders. Founded in 2012, the company targets severe rare diseases, including Leber's congenital amaurosis type 10 and Usher syndrome type 2. ProQR's leading product candidates include sepofarsen, currently in a phase II/III clinical trial for Leber's congenital amaurosis 10, QR-421a in a phase 1/2 trial for Usher syndrome type 2 and non-syndromic retinitis pigmentosa, QR-1123 in a phase 1/2 trial for autosomal dominant retinitis pigmentosa, and QR-504a, which is undergoing its first clinical trial for Fuchs endothelial corneal dystrophy. The company has established license agreements with several prominent medical institutions, including General Hospital Corporation and Radboud University Medical Center.

Crescendo Biologics Limited is a clinical-stage biotechnology company based in Cambridge, United Kingdom, specializing in the development of innovative therapies for oncology and dermatology. The company focuses on creating multi-specific immune-oncology modulators and Humabody Drug Conjugates using its proprietary transgenic mouse platform. This technology allows for the in vivo maturation of human VH domains, optimizing their affinity and biophysical properties for therapeutic use. Crescendo Biologics aims to address critical challenges in generating high-affinity, soluble human VH antibody fragments, which are recognized for their potential as effective therapeutics. By leveraging its advanced platforms, the company is engaged in the product development of in-house targets as well as collaborations with other organizations to enhance the efficacy of cancer treatments. Founded in 2007 and originally known as Translocus Limited, Crescendo Biologics has established itself as a leader in the field of next-generation antibody therapeutics.

MISSION Therapeutics is a biotechnology company specializing in developing drugs that target the cellular process of deubiquitylation for the treatment of cancer and other diseases. Their focus is on developing small molecule drugs that selectively inhibit specific deubiquitylating enzymes (DUBs), which play crucial roles in regulating protein degradation and cellular processes. These drugs aim to intervene in disease mechanisms where DUB dysregulation is implicated, offering potential therapeutic benefits.

Synthace Limited is a London-based company specializing in the development and operation of software solutions for various industries, including health, pharmaceuticals, food, energy, agri-science, industrial biotechnology, and manufacturing. The company offers Antha, a cloud-based platform designed to automate and enhance biological processes. This platform allows life science researchers to digitize experiments from start to finish, enabling them to design, simulate, and execute reproducible experiments with minimal training. Antha facilitates the integration of experimental data and metadata in a streamlined manner, making it easier for scientists to manage their workflows and increasing the scientific value of their research. Synthace's technology empowers researchers to conduct complex experiments without the need for coding, thereby expanding the possibilities of laboratory experimentation. Founded in 2011, Synthace also has a presence in Cambridge, Massachusetts, and maintains a strategic partnership with Microsoft.

ProQR Therapeutics N.V. is a biopharmaceutical company based in Leiden, the Netherlands, focused on the discovery and development of RNA-based therapeutics for genetic disorders. Founded in 2012, the company targets severe rare diseases, including Leber's congenital amaurosis type 10 and Usher syndrome type 2. ProQR's leading product candidates include sepofarsen, currently in a phase II/III clinical trial for Leber's congenital amaurosis 10, QR-421a in a phase 1/2 trial for Usher syndrome type 2 and non-syndromic retinitis pigmentosa, QR-1123 in a phase 1/2 trial for autosomal dominant retinitis pigmentosa, and QR-504a, which is undergoing its first clinical trial for Fuchs endothelial corneal dystrophy. The company has established license agreements with several prominent medical institutions, including General Hospital Corporation and Radboud University Medical Center.

NuCana plc is a UK-based, clinical-stage biopharmaceutical company dedicated to developing innovative cancer treatments. It specializes in transforming widely-used chemotherapy agents into more effective and safer medicines using its proprietary ProTide technology. NuCana's pipeline includes Acelarin, in Phase III trials for biliary tract and metastatic pancreatic cancers, and NUC-3373 & NUC-7738, in Phase I trials for advanced solid tumors. The company collaborates with academic institutions for research and licensing agreements. NuCana was established in 1997 and is headquartered in Edinburgh, with a focus on the U.S. market.

NuCana plc is a UK-based, clinical-stage biopharmaceutical company dedicated to developing innovative cancer treatments. It specializes in transforming widely-used chemotherapy agents into more effective and safer medicines using its proprietary ProTide technology. NuCana's pipeline includes Acelarin, in Phase III trials for biliary tract and metastatic pancreatic cancers, and NUC-3373 & NUC-7738, in Phase I trials for advanced solid tumors. The company collaborates with academic institutions for research and licensing agreements. NuCana was established in 1997 and is headquartered in Edinburgh, with a focus on the U.S. market.

MISSION Therapeutics is a biotechnology company specializing in developing drugs that target the cellular process of deubiquitylation for the treatment of cancer and other diseases. Their focus is on developing small molecule drugs that selectively inhibit specific deubiquitylating enzymes (DUBs), which play crucial roles in regulating protein degradation and cellular processes. These drugs aim to intervene in disease mechanisms where DUB dysregulation is implicated, offering potential therapeutic benefits.

ABIONYX Pharma SA is a French biopharmaceutical company established in 2005, currently based in Labege. It specializes in the discovery and development of therapies targeting high-density lipoprotein (HDL) for treating cardiovascular and metabolic diseases. The company's primary focus is on developing HDL mimetics to rapidly regress atherosclerotic plaque in high-risk patients. Its lead product candidate, CER-001, is a Phase II clinical trial asset designed to mimic the properties of pre-beta HDL for treating post-acute coronary syndrome patients and familial primary hypoalphalipoproteinemia patients. Additionally, ABIONYX Pharma has another drug candidate, CER-209, in Phase I trials for metabolic diseases and liver-related conditions such as atherosclerosis and non-alcoholic steato-hepatitis.

Crescendo Biologics Limited is a clinical-stage biotechnology company based in Cambridge, United Kingdom, specializing in the development of innovative therapies for oncology and dermatology. The company focuses on creating multi-specific immune-oncology modulators and Humabody Drug Conjugates using its proprietary transgenic mouse platform. This technology allows for the in vivo maturation of human VH domains, optimizing their affinity and biophysical properties for therapeutic use. Crescendo Biologics aims to address critical challenges in generating high-affinity, soluble human VH antibody fragments, which are recognized for their potential as effective therapeutics. By leveraging its advanced platforms, the company is engaged in the product development of in-house targets as well as collaborations with other organizations to enhance the efficacy of cancer treatments. Founded in 2007 and originally known as Translocus Limited, Crescendo Biologics has established itself as a leader in the field of next-generation antibody therapeutics.

GlycoVaxyn AG is a biopharmaceutical company based in Schlieren, Switzerland, specializing in the development and manufacture of biological conjugation vaccines targeting bacterial infections. Established in 2004, the company employs recombinant DNA technology to create immunogenic glycoprotein conjugate vaccines for various bacterial diseases, including pneumococcal and nosocomial infections. GlycoVaxyn's innovative approach allows for the conjugation of carbohydrates to proteins, resulting in well-characterized molecules that demonstrate high consistency and reproducibility across batches. This technology is instrumental in creating new prophylactic and therapeutic vaccines, contributing to the prevention and treatment of bacterial infections. As of February 2015, GlycoVaxyn operates as a subsidiary of GlaxoSmithKline plc.

Ocera Therapeutics is a clinical-stage biopharmaceutical company dedicated to developing and commercializing innovative treatments for patients suffering from acute and chronic liver diseases. The company's primary focus is on its lead product, OCR-002, an ammonia scavenger designed to address hyperammonemia through both intravenous and oral formulations. Recently, Ocera completed a Phase 2b clinical trial, known as STOP-HE, which assessed the safety and efficacy of OCR-002 in alleviating neurocognitive symptoms associated with acute hepatic encephalopathy in hospitalized patients with elevated ammonia levels. Ocera is currently preparing for a meeting with the FDA to discuss the intravenous program and potential future development pathways for its therapeutics.

Fovea Pharmaceuticals is a French biopharmaceutical company established in 2005, specializing in the discovery and development of drugs for ocular diseases. Based in Paris, Fovea focuses on creating innovative treatments for various eye conditions, including allergic conjunctivitis, hereditary angioedema, diabetic macular edema, and retinitis pigmentosa. The company's key products include FOV1101 Prednisporin, FOV2302, FOV2304, and FOV2501, which address a range of ocular disorders and associated complications. As of October 2009, Fovea operates as a subsidiary of Sanofi, enhancing its capabilities to deliver effective therapies for vision-related health issues.

GlycoVaxyn AG is a biopharmaceutical company based in Schlieren, Switzerland, specializing in the development and manufacture of biological conjugation vaccines targeting bacterial infections. Established in 2004, the company employs recombinant DNA technology to create immunogenic glycoprotein conjugate vaccines for various bacterial diseases, including pneumococcal and nosocomial infections. GlycoVaxyn's innovative approach allows for the conjugation of carbohydrates to proteins, resulting in well-characterized molecules that demonstrate high consistency and reproducibility across batches. This technology is instrumental in creating new prophylactic and therapeutic vaccines, contributing to the prevention and treatment of bacterial infections. As of February 2015, GlycoVaxyn operates as a subsidiary of GlaxoSmithKline plc.

ABIONYX Pharma SA is a French biopharmaceutical company established in 2005, currently based in Labege. It specializes in the discovery and development of therapies targeting high-density lipoprotein (HDL) for treating cardiovascular and metabolic diseases. The company's primary focus is on developing HDL mimetics to rapidly regress atherosclerotic plaque in high-risk patients. Its lead product candidate, CER-001, is a Phase II clinical trial asset designed to mimic the properties of pre-beta HDL for treating post-acute coronary syndrome patients and familial primary hypoalphalipoproteinemia patients. Additionally, ABIONYX Pharma has another drug candidate, CER-209, in Phase I trials for metabolic diseases and liver-related conditions such as atherosclerosis and non-alcoholic steato-hepatitis.